ARTICLE | Financial News
Oyster Point raises $93M series B to bring dry eye nasal spray to FDA
March 1, 2019 1:31 AM UTC
Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.
Invus Opportunities and Flying L Partners co-led the round in collaboration with Falcon Vision. Existing investors New Enterprise Associates and Versant Ventures, as well as new investor Vida Ventures, also participated in the round...
BCIQ Company Profiles